Metabolomic profile of children with recurrent respiratory infections

Pharmacological Research

Volumn 115, Issue , 2017, Pages 162-167

  Bozzetto, Sara ^a   Pirillo, Paola ^a   Carraro, Silvia ^a   Berardi, Mariangela ^a   Cesca, Laura ^a   Stocchero, Matteo ^b   Giordano, Giuseppe ^a   Zanconato, Stefania ^a   Baraldi, Eugenio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b S IN Soluzioni Informatiche   (Italy)

Author keywords

Children; Immunostimulants; Metabolomics; Pidotimod; Recurrent respiratory infections

Indexed keywords

BIOLOGICAL MARKER; ISOPROTEIN; PIDOTIMOD;

AGE DISTRIBUTION; ARTICLE; BIOCHEMICAL ANALYSIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; FEMALE; HUMAN; INTESTINE FLORA; MALE; MASS SPECTROMETRY; METABOLOMICS; MICROBIOME; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS; METABOLISM; MICROFLORA; MULTIVARIATE ANALYSIS; PHYSIOLOGY; PROCEDURES; URINE;

BIOMARKERS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; MICROBIOTA; MULTIVARIATE ANALYSIS; PILOT PROJECTS; RESPIRATORY TRACT INFECTIONS;

EID: 84999287017     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.11.007     Document Type: Article

References (24)

1. [1] De Martino, M., Ballotti, S., The child with recurrent respiratory infections: normal or not?. Pediatr. Allergy Immunol. 18 (2007), 13–18.
2. [2] Martinez, F.D., The origins of asthma and chronic obstructive pulmonary disease in early life. Proc. Am. Thorac. Soc. 6 (2009), 272–277.
3. [3] Del-Rio-Navarro, B.E., Espinosa Rosales, F., Flenady, V., Sienra-Monge, J.J., Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Syst. Rev., 2006, CD004974.
4. [4] Esposito, S., Musio, A., Immunostimulants and prevention of recurrent respiratory tract infections. J. Biol. Regul. Homeost. Agents 27 (2013), 627–636.
5. [5] Jackson, D.J., Hartert, T.V., Martinez, F.D., Weiss, S.T., Asthma, Fahy J.V., NHLBI Workshop on the primary prevention of chronic lung diseases. Ann Am Thorac Soc. 3 (2014), 139–145.
6. [6] Carta, S., Silvestri, M., Rossi, G.A., Modulation of airway epithelial cell functions by pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression. Ital. J. Pediatr., 39, 2013, 29.
7. [7] Ferrario, B.E., Garuti, S., Braido, F., Canonica, G.W., Pidotimod: the state of the art. Clin. Mol. Allergy, 13, 2015, 8.
8. [8] Namazova-Baranova, L.S., Alekseeva, A.A., Kharit, S.M., Kozhevnikova, T.N., Taranushenko, T.E., Tuzankina, I.A., Scarci, F., Efficacy and safety of pidotimod in the prevention of recurrent respiratory infections in children: a multicentre study. Int. J. Immunopathol. Pharmacol. 27 (2014), 413–419.
9. [9] Zuccotti, G.V., Mameli, C., Trabattoni, D., Beretta, S., Biasin, M., Guazzarotti, L., Clerici, M., Immunomodulating activity of pidotimod in children with Down syndrome. J. Biol. Regul. Homeost. Agents 27 (2013), 253–258.
10. [10] Mameli, C., Pasinato, A., Picca, M., Bedogni, G., Pisanelli, S., Zuccotti, G.V., AX-Working group, Pidotimod for the prevention of acute respiratory infections in healthy children entering into daycare: a double-blind randomized placebo-controlled study. Pharmacol. Res. 97 (2015), 79–83.
11. [11] Esposito, S., Garziano, M., Rainone, V., Trabattoni, D., Biasin, M., Senatore, L., Marchisio, P., Rossi, M., Principi, N., Clerici, M., Immunomodulatory activity of pidotimod administered with standard antibiotic therapy in children hospitalized for community-acquired pneumonia. J. Transl. Med., 13, 2015, 288.
12. [12] Carraro, S., Giordano, G., Remiero Perilongo, G., Baraldi, E., Metabolomics: a new frontier for research in pediatrics. J. Pediatr. 154 (2009), 638–644.
13. [13] Nicholson, J.K., Lindon, J.C., Systems biology: metabonomics. Nature 455 (2008), 1054–1056.
14. [14] Mussap, M., Antonucci, R., Noto, A., Fanos, V., The role of metabolomics in neonatal and pediatric laboratory medicine. Clin. Chim. Acta 426 (2013), 127–138.
15. [15] van den Berg, R.A., Hoefsloot, H.C., Westerhuis, J.A., Smilde, A.K., van der Werf, M.J., Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics, 7, 2006, 142.
16. [16] Stocchero, M., Paris, D., Post-transformation of PLS2 (ptPLS2) by orthogonal matrix: a new approach for generating predictive and orthogonal latent variables. J. Chemom. 30:5 (2006), 242–251, 10.1002/cem.2780.
17. [17] Wehrens, R., Franceschi, P., Vrhovsek, U., Mattivi, F., Stability-based biomarker selection. Anal. Chim. Acta 705 (2011), 15–23.
18. [18] Chong, I.G., Jun, C.H., Performance of some variable selection methods when multicollinearity is present. Chemometr. Intell. Lab. 78 (2005), 103–112.
19. [19] Westerhuis, J.A., Hoefsloot, H.C.J., Smit, S., Vis, D.J., Smilde, A.K., van Elzen, E.J.J., van Duijnhoven, J.P.M., van Dorsten, F.A., Assessment of PLSDA cross validation. Metabolomics 4 (2008), 81–89.
20. [20] Goodwin, B.L., Ruthven, C.R.J., Sandler, M., Gut flora and the origin of some urinary aromatic phenolic compounds. Biochem. Pharmacol. 147 (1994), 2294–2297.
21. [21] Claus, S.P., Tsang, T.M., Wang, Y., Cloarec, O., Skordi, E., Martin, F.P., Rezzi, S., Ross, A., Kochhar, S., Holmes, E., Nicholson, J.K., Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol. Syst. Biol., 4, 2008, 219.
22. [22] Ridlon, J.M., Kang, D.J., Hylemon, P.B., Bajaj, J.S., Bile acids and the gut microbiome. Curr. Opin. Gastroenterol. 30 (2014), 332–338.
23. [23] Marsland, B.J., Trompette, A., Gollwitzer, E.S., The gut-lung axis in respiratory disease. Ann. Am. Thorac. Soc. 12:Suppl. 2 (2015), S150–156.
24. [24] Samuelson, D.R., Welsh, D.A., Shellito, J.E., Regulation of lung immunity and host defense by the intestinal microbiota. Front. Microbiol., 6, 2015, 1085.